相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of therapeutic antibodies for the treatment of diseases
Ruei-Min Lu et al.
JOURNAL OF BIOMEDICAL SCIENCE (2020)
Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer
Bing-Lan Zhang et al.
HUMAN GENE THERAPY (2019)
Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach
Michail Nikolaou et al.
INTEGRATIVE CANCER THERAPIES (2019)
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Mohamed-Reda Benmebarek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
James L. Gulley et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
Hyun Tae Lee et al.
MOLECULES (2019)
Recombinant AAV-CEA Tumor Vaccine in Combination with an Immune Adjuvant Breaks Tolerance and Provides Protective Immunity
Jonathan A. Hensel et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Cancer Vaccines
Peter J. DeMaria et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2019)
Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
Jason Chesney et al.
BRITISH JOURNAL OF CANCER (2019)
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety
Steven S. Raman et al.
IMMUNOTHERAPY (2019)
Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12
Xiaowei Chi et al.
CANCER MEDICINE (2019)
The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer
Nanna Jorgensen et al.
FRONTIERS IN IMMUNOLOGY (2019)
A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts
R. Lazaro-Gorines et al.
SCIENTIFIC REPORTS (2019)
Engineered T Cell Therapy for Cancer in the Clinic
Lijun Zhao et al.
FRONTIERS IN IMMUNOLOGY (2019)
Cytokines in clinical cancer immunotherapy
Pedro Berraondo et al.
BRITISH JOURNAL OF CANCER (2019)
The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design
Matthieu Besneux et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The Intriguing History of Cancer Immunotherapy
Paula Dobosz et al.
FRONTIERS IN IMMUNOLOGY (2019)
Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma
Edward A. Stadtmauer et al.
BLOOD ADVANCES (2019)
Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion
Michael R. Bishop et al.
BLOOD ADVANCES (2019)
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment
Marina Martinez et al.
FRONTIERS IN IMMUNOLOGY (2019)
Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration's Adverse Event Reporting System, 2010-2017
Graca M. Dores et al.
JAMA NETWORK OPEN (2019)
Current Progress in CAR-T Cell Therapy for Solid Tumors
Shuo Ma et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion
Wei Geng et al.
MOLECULAR MEDICINE REPORTS (2018)
Phase II Clinical Trial to Evaluate the Efficacy of Transanal Endoscopic Total Mesorectal Excision for Rectal Cancer
Sung Chan Park et al.
DISEASES OF THE COLON & RECTUM (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma
Katarzyna C. Pituch et al.
MOLECULAR THERAPY (2018)
Driving T-cell immunotherapy to solid tumors
Ken Garber
NATURE BIOTECHNOLOGY (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Talimogene laherparepvec: First in class oncolytic virotherapy
Robert M. Conry et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases
Michael S. Magee et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
Elena Garcia-Martinez et al.
ONCOIMMUNOLOGY (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
Katherine C. Pehlivan et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer)
Zong Sheng Guo
BMC CANCER (2018)
Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges
N. A. Nixon et al.
CURRENT ONCOLOGY (2018)
Roles of the immune system in cancer: from tumor initiation to metastatic progression
Hugo Gonzalez et al.
GENES & DEVELOPMENT (2018)
A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release
Yiyang Xu et al.
CELL DISCOVERY (2018)
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
T. Yoshino et al.
ANNALS OF ONCOLOGY (2018)
Immunotherapy as an Option for Cancer Treatment
Tillmann Rusch et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2018)
MICROSATELLITE INSTABILITY IN COLORECTAL CANCER
Jafar Nouri Nojadeh et al.
EXCLI JOURNAL (2018)
EVALUATION OF MICROSATELLITE INSTABILITY IN TUMOR AND TUMOR MARGINAL SAMPLES OF SPORADIC COLORECTAL CANCER USING MONONUCLEOTIDE MARKERS
Jafar Nouri Nojadeh et al.
EXCLI JOURNAL (2018)
Global patterns and trends in colorectal cancer incidence and mortality
Melina Arnold et al.
GUT (2017)
PD-1 and its ligands are important immune checkpoints in cancer
Yinan Dong et al.
ONCOTARGET (2017)
5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798)
Itamar Gonzalez-Perera et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2017)
Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immunotherapy in hematologic malignancies: past, present, and future
Annie Im et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers
Chengcheng Zhang et al.
MOLECULAR THERAPY (2017)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Therapeutic T cell engineering
Michel Sadelain et al.
NATURE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Melanoma antigen A12 regulates cell cycle via tumor suppressor p21 expression
Teruki Yanagi et al.
Oncotarget (2017)
Inflammatory responses and inflammation-associated diseases in organs
Linlin Chen et al.
Oncotarget (2017)
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
Kristen M. Hege et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
EpCAM-expressing circulating tumor cells in colorectal cancer
Chiara Nicolazzo et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2017)
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
Atsuko Kitano et al.
ESMO OPEN (2017)
Colorectal cancer statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Clinical relevance of colorectal cancer molecular subtypes
Nuria Rodriguez-Salas et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
Guocan Wang et al.
CANCER DISCOVERY (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trialaEuro
T. K. Eigentler et al.
ANNALS OF ONCOLOGY (2016)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
Yaxian Kong et al.
CLINICAL CANCER RESEARCH (2016)
Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma
Naoya Yamazaki et al.
JOURNAL OF DERMATOLOGY (2016)
MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases
Sid P. Kerkar et al.
JOURNAL OF IMMUNOTHERAPY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non muscle-invasive bladder cancer
J. Alfred Witjes et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
Prognostic value of MAGE-A9 expression in patients with colorectal cancer
Weipeng Zhan et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2016)
Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
Xiao-Yi Tang et al.
BMJ OPEN (2016)
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Marios Giannakis et al.
CELL REPORTS (2016)
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Xiuyan Wang et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
Shinichi Kageyama et al.
CLINICAL CANCER RESEARCH (2015)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer
Hisato Kawakami et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street
David M. Barrett et al.
JOURNAL OF IMMUNOLOGY (2015)
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport et al.
NATURE MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Randomized Trial of Laparoscopic versus Open Surgery for Rectal Cancer
H. Jaap Bonjer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cancer and the Immune System: Basic Concepts and Targets for Intervention
Drew Pardoll
SEMINARS IN ONCOLOGY (2015)
The High-Dose Aldesleukin Select Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
David F. McDermott et al.
CLINICAL CANCER RESEARCH (2015)
Adoptive T Cell Immunotherapy for Cancer
Karlo Perica et al.
RAMBAM MAIMONIDES MEDICAL JOURNAL (2015)
The Promise of Preventive Cancer Vaccines
Pier-Luigi Lollini et al.
VACCINES (2015)
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2014)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma
Marijo Bilusic et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Bacillus Calmette-Guerin Strain Differences Have an Impact on Clinical Outcome in Bladder Cancer Immunotherapy
Cyrill A. Rentsch et al.
EUROPEAN UROLOGY (2014)
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer
Brian S. Henick et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Evaluating the significance of expression of CEA mRNA and levels of CEA and its related proteins in colorectal cancer patients
Wenyuan Wang et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
T Cell Receptor Signaling Can Directly Enhance the Avidity of CD28 Ligand Binding
Mariano Sanchez-Lockhart et al.
PLOS ONE (2014)
EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma
Hongsheng Miao et al.
PLOS ONE (2014)
Colorectal cancer and immunity: what we know and perspectives
Simon Pernot et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Classification of current anticancer immunotherapies
Lorenzo Galluzzi et al.
ONCOTARGET (2014)
Overexpressed oncogenic tumor-self antigens New vaccine targets
Robert K. Bright et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity
Henri-Alexandre Michaud et al.
ONCOIMMUNOLOGY (2014)
A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer
Michael A. Morse et al.
ANNALS OF SURGERY (2013)
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Gerald P. Linette et al.
BLOOD (2013)
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Joel Crespo et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Richard A. Morgan et al.
JOURNAL OF IMMUNOTHERAPY (2013)
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Andrew M. Intlekofer et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H. J. Schmoll et al.
ANNALS OF ONCOLOGY (2012)
Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis
M. B. Garg et al.
BRITISH JOURNAL OF CANCER (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Natural Innate and Adaptive Immunity to Cancer
Matthew D. Vesely et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29 (2011)
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
Cor H. J. Lamers et al.
BLOOD (2011)
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2011)
Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer
Tomasz M. Beer et al.
CLINICAL CANCER RESEARCH (2011)
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy
Carlos A. Ramos et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
Seigo Terawaki et al.
JOURNAL OF IMMUNOLOGY (2011)
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
Maria R. Parkhurst et al.
MOLECULAR THERAPY (2011)
Cancer Immunotherapy: Sipuleucel-T and Beyond
Aimee E. Hammerstrom et al.
PHARMACOTHERAPY (2011)
State of the Art in Tumor Antigen and Biomarker Discovery
Klervi Even-Desrumeaux et al.
Cancers (2011)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The safety and side effects of monoclonal antibodies
Trevor T. Hansel et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Laura A. Johnson et al.
BLOOD (2009)
Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer
Frank M. Speetjens et al.
CLINICAL CANCER RESEARCH (2009)
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
Neil N. Senzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer
Howard L. Kaufman et al.
CLINICAL CANCER RESEARCH (2008)
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
James L. Gulley et al.
CLINICAL CANCER RESEARCH (2008)
Strategies used for MUC1 immunotherapy: human clinical studies
Choon-Kit Tang et al.
EXPERT REVIEW OF VACCINES (2008)
Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy
Khoi Q. Tran et al.
JOURNAL OF IMMUNOTHERAPY (2008)
CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
Chrysoula I. Liakou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: Implications for self-tolerance and tumor therapy
Silvie Cloosen et al.
CANCER RESEARCH (2007)
Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen
Asim Saha et al.
CANCER RESEARCH (2007)
Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys (R)) versus interferon alpha-2a (Roferon (R)-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia
Jeffrey H. Lipton et al.
LEUKEMIA & LYMPHOMA (2007)
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C. C. Hu et al.
CLINICAL CANCER RESEARCH (2006)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege
Takashi Ishida et al.
CANCER RESEARCH (2006)
A phase I trial of pox PSA vaccines (PROSTVAC®-VF) with b7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in patients with prostate cancer -: art. no. 1
RS DiPaola et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2006)
Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells
M Kisielow et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Monoclonal versus polyclonal antibodies: Distinguishing characteristics, applications, and information resources
NS Lipman et al.
ILAR JOURNAL (2005)
Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study
M Michallet et al.
LEUKEMIA (2004)
Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer:: A phase 2 trial
PA Burch et al.
PROSTATE (2004)
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
OH Brekke et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Expression of programmed death 1 ligands by murine T cells and APC
T Yamazaki et al.
JOURNAL OF IMMUNOLOGY (2002)
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2
MH Kershaw et al.
HUMAN GENE THERAPY (2002)
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
MJ Scanlan et al.
IMMUNOLOGICAL REVIEWS (2002)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
RC Flanigan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
分享论文
